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Bovine leukemia virus (BLV) Tax protein, a transcriptional activator of viral expression, is essential for viral
replication in vivo. Tax is believed to be involved in leukemogenesis because of its second function, immor-
talization of primary cells in vitro. These activities of Tax can be dissociated on the basis of point mutations
within specific regions of the protein. For example, mutation of the phosphorylation sites at serines 106 and
293 abrogates immortalization potential in vitro but maintains transcriptional activity. This type of mutant is
thus particularly useful for unraveling the role of Tax immortalization activity during leukemogenesis inde-
pendently of viral replication. In this report, we describe the biological properties of BLV recombinant pro-
viruses mutated in the Tax phosphorylation sites (BLVTax1061293). Titration of the proviral loads by semi-
quantitative PCR revealed that the BLV mutants propagated at wild-type levels in vivo. Furthermore, two
animals (sheep 480 and 296) infected with BLVTax1061293 developed leukemia or lymphosarcoma after 16
and 36 months, respectively. These periods of time are within the normal range of latencies preceding the onset
of pathogenesis induced by wild-type viruses. The phenotype of the mutant-infected cells was characteristic of
a B lymphocyte (immunoglobulin M positive) expressing CD11b and CD5 (except at the final stage for the lat-
ter marker), a pattern that is typical of wild-type virus-infected target cells. Interestingly, the transformed B
lymphocytes from sheep 480 also coexpressed the CD8 marker, a phenotype rarely observed in tumor biopsies
from chronic lymphocytic leukemia patients. Finally, direct sequencing of the tax gene demonstrated that the
leukemic cells did not harbor revertant proviruses. We conclude that viruses expressing a Tax mutant unable
to transform primary cells in culture are still pathogenic in the sheep animal model. Our data thus provide a
clear example of the discordant conclusions that can be drawn from in vitro immortalization assays and in vivo
experiments. These observations could be of interest for other systems, such as the related human T-cell
leukemia virus type 1, which currently lack animal models allowing the study of the leukemogenic process.
Bovine leukemia virus (BLV) and human T-cell leukemia
virus type 1 (HTLV-I) are members of the Deltaretrovirus ge-
nus in the Retroviridae family (6, 18, 28, 30, 54, 69, 78, 81, 82).
In addition to the structural genes required for the synthesis of
the viral particle (gag, pol, and env), these viruses also contain
a region X located at the 39 end of their genome. This region
encodes a series of proteins involved in the regulation of viral
expression (Tax, Rex, R3, and G4 for BLV). Among these, the
Tax protein is a 34- to 38-kDa transcriptional activator which
increases the synthesis of all viral mRNAs (15, 71). Transacti-
vation by Tax requires 21-bp imperfect repeats located in the 59
long terminal repeat (LTR). In fact, Tax does not bind directly
to DNA but interacts with the CREB/ATF cellular proteins
and increases their affinity for the 21-bp enhancer elements (1,
2, 8). Although some limited variation might be compatible
with function, tax is an essential gene that is absolutely re-
quired for infectivity in vivo (77). Besides its transactivation
activity, the Tax protein also exhibits another property in cell
culture: its expression induces immortalization of primary rat
embryo fibroblasts (REF) (74). In addition, coexpression of tax
and the Ha-ras oncogene fully transforms REF cells yielding
tumors in nude mice. These Tax activities can be dissociated by
mutations within specific regions of the protein. For example,
transcriptional activity requires an amino-terminal zinc finger
structure and an internal leucine-rich activation domain (72,
76). Conversely, phosphorylation of Tax at serines 106 and 293
is required for in vitro transformation but not for transactiva-
tion (73). These phosphorylation-deficient Tax mutants should
thus provide a unique opportunity to correlate in vitro trans-
formation assays with pathogenicity in vivo.
During the last decades, several methods have been de-
signed to unravel the oncogenic potential of selected viral
proteins. One of the earliest-developed techniques, which was
described in 1983 (36, 37), is based on the immortalization of
primary REF. This method also allowed the characterization
of two types of oncogenes: those that indefinitely prolong the
cellular lifespan (like Myc), and others that induce transfor-
mation by altering cell morphology, impeding contact inhibi-
tion, and decreasing growth factor requirements (such as Ras).
Both kinds of oncogenes are able to cooperate in order to yield
fully transformed cells that induce tumors in nude mice. Sim-
ilar studies in the BLV-HTLV field have shown that one of the
viral regulatory proteins, called Tax, is able to functionally
substitute for Myc in this type of assay (53, 74). A slightly
modified version of this protocol utilizes murine cell lines
(Rat-1 or -2) in which the tax gene provokes the formation of
transformed foci upon transfection (19, 42, 63, 66, 79, 80). The
main objection against these approaches concerns the cell type
(fibroblast versus lymphocyte) and the origin of the species
(murine instead of human, ovine, or bovine). Therefore, other
cell culture systems utilizing T or B lymphocytes have been
developed (3, 16, 22, 23, 47, 55–58, 70). Among these, proto-
cols using recombinant proviruses and primary lymphocytes
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probably provide the most relevant information. Unfortu-
nately, this type of technique has not been established for
BLV. The conclusions drawn from these different studies have
been a matter of dispute, in particular those concerning the
pathways involved in transformation. For instance, the ability
of HTLV-1 Tax to transform primary rat embryo fibroblasts
requires its potential to activate the CArG element, whereas
NFkB activity is essential in Rat-1 cells (42). The situation
appears to be far more complex in cell culture systems based
on T lymphocytes. Indeed, the NFkB function of Tax-I appears
to be sufficient to promote growth response to interleukin-2,
but clonal expansion of CD41 cells requires the CREB/ATF
and SRF pathways (3).
To further understand the role of Tax during pathogenesis,
extensive efforts have been made to establish animal models in
mice, rats, rabbits, and monkeys (7, 12, 13, 17, 24–27, 29, 31, 33,
38, 48, 51, 55, 59, 60, 62, 65, 68, 83), and indeed, these systems
yielded valuable information in various aspects of viral infec-
tivity and pathogenesis. Despite this extensive progress, the
main objection of these models is that the virus is not in the
context of its natural host species environment and that none
of them perfectly conciliates all the different phenomena oc-
curring during leukemogenesis. In this context, an alternative
approach based on viruses related to HTLV, like BLV, might
provide very useful additional information.
MATERIALS AND METHODS
Animals. All sheep were maintained under controlled conditions at the Vet-
erinary and Agrochemical Research Centre (Uccle, Belgium). At regular inter-
vals of time, total leukocyte counts were determined by using a Coulter counter
ZN, and the corresponding lymphocyte numbers were calculated using the blood
formula after examination under the microscope. In parallel, the corresponding
sera were analyzed for BLV seropositivity using immunodiffusion and enzyme-
linked immunosorbent assay (ELISA) techniques. Sheep were infected with a
wild-type strain (plasmid pBLV344 in animal 235), with viruses propagating with
equivalent efficiencies and inducing pathogenesis after similar latency periods
(plasmid pBLVIX in 8, 11, 247, 292, and 293 and pBLVgag150 in 175), or with
the Tax mutant (pBLVTax1061293 in 103, 104, 296, and 480). The construction
of the pBLV344, pBLVIX, pBLVgag150, and pBLVTax1061293 recombinant
proviruses has been described elsewhere (73, 75, 77). Of note, the pBLVgag150
mutant, which was initially referred to as attenuated (75), appeared to induce
pathogenesis at later times in sheep 175. Finally, three sheep (113, 114, and 115)
were used as uninfected controls. The procedures used for infection have been
described (77). Briefly, 100 mg of circular plasmid DNA was mixed with 200 mg
of Dotap (Roche Diagnostics) and injected intradermally into the back of the
sheep.
PCRs. Aliquots of peripheral blood were collected by jugular venipuncture at
4, 6, 15, and 30 months postinfection, and crude cell lysates were prepared as
described (77). Briefly, 500 ml of blood sample was mixed with an equal volume
of lysis buffer (0.32 M sucrose, 10 mM Tris-HCl [pH 7.5], 5 mM MgCl2, 1%
Triton X-100). The samples were centrifuged for 20 s, and the pellets were
washed at least four times with 1 ml of the same buffer. The samples were then
resuspended in 500 ml of PCR buffer (10 mM Tris-HCl, 1.5 mM MgCl2, 50 mM
KCl [pH 8.3]) and incubated with 6 ml of proteinase K (5 mg/ml) for 1 h at 50°C.
Five microliters of these lysates was then amplified by PCR in the presence of 200
mM each of the four deoxynucleoside triphosphates, 200 ng of primers PCRTB
(59-CGGGGCGGTGGCGGCGCCTAGG-39) and PCRTD (59-TAACGACAA
AATTAT-TTCTTGTC-39), and 2 U of Taq DNA polymerase (Roche Diagnos-
tics). Since PCRTD is located upstream of the splice acceptor site of the tax and
rex sequences, the oligonucleotides used do not amplify DNA corresponding to
reverse-transcribed double-spliced cDNA. The reaction mixtures were dena-
tured for 5 min at 94°C and amplified by 22 cycles of PCR (30 s at 94°C, 30 s at
57°C, and 1 min at 72°C). After PCR, the amplicons were analyzed by Southern
blotting hybridization using a tax probe (1-kb insert from plasmid pSGTax).
For sequencing, the tax amplicons were prepared as described above except for
the number of cycles (36 cycles of PCR). The amplification products were
purified with Gene Elute columns (Sigma) and sequenced by PCR with primers
CAT3 (59-CCTCAGGCCTTACAACGCTTC-39) and CAT1C (59-TCCGAGG
ACAGGATGCGTTAC-39) using the double-stranded DNA Cycle Sequencing
system (Life Technologies).
Isolation of PBMCs. Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Percoll gradient centrifugation as described previously (14). Briefly,
blood samples were collected by jugular venipuncture, and PBMCs were purified
by Percoll density gradient centrifugation (Amersham-Pharmacia). Cells were
then extensively washed with phosphate-buffered saline (PBS) supplemented
with 0.075% EDTA and with PBS alone (three times each). Cell viability was
next estimated by trypan blue dye exclusion.
Titration of the major capsid protein by ELISA. Purified PBMCs were culti-
vated for 24 h at 2 3 106 cells/ml in RPMI 1640 medium supplemented with 10%
fetal bovine serum, 2 mM glutamine, 100 U of penicillin, and 100 ng of strep-
tomycin (Life Technologies) per ml. The cell supernatants were recovered and
analyzed for p24 protein expression using an ELISA procedure. Briefly, 96-well
microtiter plates (Maxisorb immunoplate; Nunc) were coated for 4 h at room
temperature with the 49G9 monoclonal antibody (300 ng in PBS per well). After
three washes with PBS-Tween 80 (0.2%), the cell culture supernatants were
added and incubated overnight at 4°C in the presence of bovine serum albumin
(0.67%) and Tween 80 (1.33%). After three washes, the presence of the p24
antigen was revealed by using two monoclonal antibodies (29C1 and 49F5) con-
jugated with horseradish peroxidase.
Flow cytometry analysis. After isolation, the PBMCs were labeled with dif-
ferent monoclonal antibodies specific for surface immunoglobulin M (IgM) (1H4
and PIg45), CD5 (CC17), CD11b (CC125), or CD8 (CC63). Optimal antibody
concentrations were determined by serial dilutions of the ascites or the hybrid-
oma cell culture supernatants. The cells were incubated in the presence of the
monoclonals for 30 min at 4°C, washed with PBS containing 10% fetal calf
serum, and labeled with isotype-specific secondary antibodies (Caltag Laborato-
ries) conjugated with fluorescein isothiocyanate or phycoerythrin. Flow cytom-
etry analyses were performed with a Becton Dickinson FACScan using the
CELLQUEST software. Ten thousand events were collected, and the results
were presented in dot plots.
A slightly different protocol was performed to determine the number of cells
expressing the p24 major capsid protein. To trigger viral expression, the PBMCs
first had to be cultivated for 1 day as described above. In addition, to label
intracellular p24 antigen with the 49G9 antibody, the cells had to be fixed in 1%
paraformaldehyde (15 min at 4°C) and permeabilized with 70% ethanol for 1 h
at 220°C.
RESULTS
Evolution of the proviral loads in sheep infected with the
BLV Tax mutants. In a previous work, we reported the iden-
tification of the major phosphorylation sites of the BLV Tax
protein at serine residues 106 and 293 (73). These two phos-
phoserines appear to be dispensable for transcriptional activa-
tion of the viral promoter and for infectivity in vivo. Indeed,
their replacement by alanines still allows transactivation of
LTR-based reporter plasmids during transient-transfection ex-
periments. In addition, inhibition of the kinase which phos-
phorylates Tax does not alter transcriptional activation in cell
culture (73). Finally, recombinant proviruses harboring serine-
to-alanine mutations at positions 106 and 293 (BLVTax1061
293) were infectious in the sheep animal model. Since tax is an
essential gene, this observation is perhaps the best evidence for
the dispensability of phosphoserines 106 and 293 during the
viral life cycle.
In order to further characterize the role of these residues in
vivo, we estimated the efficiency of viral propagation of the
BLVTax1061293 mutant in four sheep (103, 104, 296, and
480). The proviral loads were measured at regular intervals
after seroconversion by semiquantitative PCR of the tax gene.
As a control for quantification, serial 10-fold dilutions of a
positive control were analyzed in parallel (13, 103, 1003, and
1,0003; Fig. 1). At 4 months, the proviral loads in the animals
infected with the Tax mutant or with the wild-type virus were
similar. As a negative control, no tax sequences were amplified
using lysates from an uninfected sheep (NI 113). It thus ap-
pears that the Tax mutants are infectious and propagate at
wild-type levels, extending our previous observations per-
formed at earlier times after seroconversion (73). At 6 and 15
months, the proviral loads rose gradually, indicating continu-
ous viral spread within all the animals. Viral expansion ap-
peared to be particularly fast in sheep 11 despite the low levels
of virus determined at 4 months in this animal. A similar
evolution also occurred in one of the sheep infected with the
BLV Tax mutant (sheep 480). Three sheep (11, 103, and 480)
died soon after this period and could not be analyzed at later
times. In the remaining animals, the proviral loads were very
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similar at 30 months independently of the type of virus (292,
293, 104, and 296).
We conclude that the BLVTax1061293 mutant is infectious
in vivo and propagates at wild-type levels in four different sheep.
BLV Tax recombinant is leukemogenic in sheep. Among the
three sheep that succumbed during the clinical survey, two of
them (11 and 480) exhibited very high proviral loads at 15
months (Fig. 1). In contrast, sheep 103, which was infected with
the BLV Tax mutant, only yielded low viral levels. At post
mortem autopsy, this animal did not present any clinical sign
that could be characteristic of leukemia (lymphocyte counts
above 10,000/mm3). In fact, this sheep died from an accidental
cause linked to enterotoxemia. In contrast, sheep 480 and 11,
infected with BLVTax1061293 and wild-type virus, respec-
tively, harbored very high proviral loads. These animals also
contained tremendous levels of lymphocytes within the periph-
eral blood (940,500 and 402,930 cells/mm3) (Fig. 2). It thus
appears that both sheep developed leukemia independently of
the type of infecting virus. Another animal (296) infected with
BLVTax1061293 also died with leukemia after a latency pe-
riod of 3 years (Fig. 2). In contrast to sheep 480, which only
exhibited an expansion of B lymphocytes in the blood stream
(leukemia), animal 296 developed in addition a lymphoma-
lymphosarcoma characterized by tumor infiltrations in the
lymph nodes, the liver, and the kidney. Finally, sheep 104,
infected with the Tax mutant, was still alive 44 months after
seroconversion. We conclude that, during this period of
time, two animals (480 and 296) that were injected with the
BLVTax1061293 recombinant developed a pathology charac-
teristic of BLV-associated leukemia.
Wild-type and Tax mutant viruses infect and transform sim-
ilar cell types. Although BLV can infect many different cell
types in vitro, the main cell target for BLV is the B lymphocyte
in both sheep and cattle species. Elegant experiments based on
single-cell PCR have indeed revealed that BLV infects only B
cells in vivo (44). Besides surface IgM, BLV-infected B lym-
phocytes are characterized by the expression of several pro-
teins at the cell membrane (5, 43, 45, 64). The most frequently
encountered markers are CD5 and the CD11b integrin mole-
cule (41, 61). Although the virus can also infect CD11b cells,
the CD11b1 lymphocytes preferentially expand during patho-
genesis (10). In contrast, the CD5 marker is frequently lost at
the final stages of BLV transformation in the sheep host (46).
FIG. 1. Evolution of proviral loads in sheep infected with the BLV Tax
mutants. Three sheep (11, 292, and 293) were injected with plasmid pBLVIX,
which contains an infectious and pathogenic BLV provirus (clone 344). Four
other animals (103, 104, 296, and 480) were infected with pBLVTax1061293,
which is isogenic to pBLVIX except for two serine-to-alanine mutations in the
tax gene. Blood was extracted by jugular venipuncture at regular times after
seroconversion (4, 6, 15, and 30 months), and partially purified DNA was pre-
pared from the corresponding lysates. A fraction corresponding to 5 ml of blood
was amplified by 22 cycles of PCR using two primers flanking the tax gene, and
the resulting DNAs were analyzed by Southern blotting using a tax probe. Under
these conditions, the PCRs were semiquantitative, as shown by 10-fold dilutions
(13, 103, 1003, and 1,0003) of lysate 480 at 15 months. In some lanes (p), the
DNAs had to be isolated from smaller volumes of blood (50 ml instead of 500)
because of the very high lymphocyte counts. Sheep 113 is an uninfected (NI)
animal used as a negative control for PCR contaminations. Three samples are
lacking at 30 months (†) because sheep 11, 103, and 480 died at about 19 to 20
months after seroconversion. Sheep 103 died because of enterotoxemia, whereas
the other animals succumbed with leukemia or lymphosarcoma.
FIG. 2. Evolution of lymphocyte counts in BLV-infected sheep. Sheep were infected with the pBLVTax1061293 recombinant (TAX) (animals 103, 104, 296, and
480) or with viruses exhibiting wild-type (WT) behavior during pathogenesis (plasmid pBLVIX in sheep 8, 11, 247, 292, and 293; pBLV344 in 235; and pBLVgag150
in 175). Blood samples were extracted at regular intervals (routinely every month), and the number of leukocytes per microliter was determined by using a Coulter
counter ZN. The lymphocyte counts (in parentheses) were deduced from these numbers after microscopic determination of the blood formula.
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It thus appears that the phenotype of the BLV target cell is a
B lymphocyte potentially harboring CD5 and CD11b markers.
The presence of these molecules on cells infected by the
BLV Tax mutant was assessed by flow cytometry. To this end,
PBMCs were isolated from sheep 104, 296, and 480 by using
the Percoll gradient centrifugation procedure. Labeling these
cells with monoclonal antibody 1H4, which binds to surface
IgM, and their subsequent analysis by flow cytometry revealed
that the majority of the cells within the PBMC population from
sheep 296 and 480 were B lymphocytes (respectively 80 and
93%; Fig. 3A). In contrast, sheep 104 exhibited normal B-cell
counts (32% versus 22 to 29% in uninfected sheep 113, 115,
and 116). The phenotypes of these lymphocytes were com-
pared with those isolated from wild-type virus-infected sheep
exhibiting either high (animals 175, 235, and 247) or low (an-
imals 8, 292, and 293) B-cell counts within their peripheral
blood. The B-lymphocyte concentrations paralleled the provi-
ral loads, as determined by semiquantitative PCR (Fig. 3A). Of
FIG. 3. (A) Phenotype of B cells in BLV-infected sheep. A series of 12 sheep were analyzed to determine and compare the phenotypes of the B-lymphocyte
populations within the bloodstream of animals 104, 296, and 480 infected with pBLVTax1061293 (Tax mutant). Three sheep (113, 115, and 116) that were seronegative
for BLV were used as controls, whereas six others were infected with viruses exhibiting wild-type behavior during pathogenesis (8, 292, 293, 247, 175, and 235). The
different samples were classified in the figure on basis of the proviral loads as determined by semiquantitative PCR. In some lanes (p), the lysates were diluted 10-fold
prior to PCR. PBMCs were isolated form the bloodstream and purified by Percoll gradient centrifugation. The cells were then labeled with monoclonal antibodies 1H4,
CC17, and CC125, which recognize surface IgM, CD5, and CD11b, respectively. A similar protocol was applied for labeling the major capsid protein p24 with 49G9
except that the cells were first cultivated for 24 h to trigger viral expression. Discrimination of the different cell populations was performed by two-color flow cytometry.
The data, represented as percentage of the total PBMC population (6 the corresponding standard deviation), were deduced from three independent experiments
performed over a period of several weeks. When the standard deviation is not indicated (a), the results are the mean values of only two analyses. (B) Titration of the
major capsid protein p24 after short-term culture. PBMCs were isolated from the sheep indicated and cultivated for 24 h. Then, the p24 antigen was titrated in the
cell culture supernatants by using the ELISA procedure. The data, represented as optical densities, derive from three independent experiments. (C) Expression of CD8
marker on B lymphocytes from sheep 480. PBMCs from six representative sheep infected either with wild-type viruses (292, 175, and 235) or the Tax mutant (104, 296,
and 480) were double-labeled with monoclonal antibodies 1H4 and CC63, specific for surface IgM B lymphocytes and CD8, respectively. The cells were then analyzed
by two-color flow cytometry, and results from a representative experiment (out of three) are shown as dot plots.
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note, the samples corresponding to sheep harboring very high
viral loads (marked with an asterisk) were diluted 10-fold prior
to amplification. Among the B-cell population from sheep 104
infected with the Tax mutant, a minority of lymphocytes har-
bored the CD5 marker (32% B versus 7% B CD51), but most
of them were CD11b positive (32% B versus 27% B CD111).
These values are within the normal range observed in wild-type
virus-infected animals at similar viral loads (sheep 8, 292, and
293). At the leukemic stage, when the circulating blood con-
tains almost pure populations of B cells (around 90% or more),
expression of the CD5 molecule was only poorly associated
with the transformed lymphocytes. Indeed, only one animal
(235) contained high levels of B CD51 cells (51%; Fig. 3A). In
contrast, CD11b appeared to be a far better marker for the
transformed B lymphocytes both in Tax mutant- and in wild-
type virus-infected sheep (between 34 and 62%). There was,
however, no significant and systematic difference between
these two categories of infected animals.
We next analyzed the ability of the wild-type and Tax mutant
viruses to be expressed during ex vivo cell cultivation. In vivo,
BLV is a hiding pathogen which is rarely expressed within the
infected lymphocyte population, but isolation and cultivation
of the infected PBMCs permits the evaluation of viral protein
synthesis (34, 52). BLV expression was estimated by two com-
plementary techniques, ELISA and flow cytometry, based on
the synthesis of the major capsid protein p24. In the asymp-
tomatic sheep, the B-cell population expressing the p24 anti-
gen (i.e., double-positive B1 p241 cells) accounted for 15 to
18% of the PBMCs independently of the type of infecting virus
(Fig. 3A, compare 8, 292, 293, and 104). Among the animals
harboring high viral loads, ex vivo p24 synthesis becomes in-
efficient, particularly at the final stages of leukemogenesis.
Despite tremendous levels of B lymphocytes (around 90% of
the PBMCs), less than 5% of the cells were p24 positive both
in wild-type and in Tax mutant cell populations (Fig. 3A, sheep
175, 235, 247, 296, and 480). The total amount of p24 expressed
in the culture supernatants, as measured by ELISA, generally
paralleled nicely the percentages of cells revealed by flow cy-
tometry (Fig. 3B). The sole exception was sheep 296, infected
by the Tax mutant, whose PBMCs expressed significant levels
of p24 protein in the culture medium despite low numbers of
p24-positive cells as revealed by flow cytometry. It should be
mentioned, however, that the total amounts of p24 corre-
sponding to this particular animal also dropped just before
death (data not shown). We conclude that the mean levels of
p24 and their evolution at different stages of pathogenesis are
similar in all the infected sheep, independently of the type of
virus.
Interestingly, during the characterization of the cell pheno-
types, we observed high numbers of CD8-positive cells in sheep
480, which was infected by the Tax mutant virus. In fact, most
of the B-cell population harbored this marker, as revealed by
double staining and flow cytometry (Fig. 3C, 480). The expres-
sion of the CD8 molecule was confirmed by using two inde-
pendent antibodies (CC63 and ST8), and transcription of the
corresponding gene was verified by RNA hybridization (data
not shown). In addition, two independent antibodies (1H4 and
PIg45) confirmed that the leukemic cells were B lymphocytes.
Such a B/CD8 phenotype was not associated with cells from
other animals harboring either high (175, 235, and 296) or low
(104 and 292) viral loads. More specifically, the CD8 molecule
was not expressed at the surface of the leukemic B lymphocytes
from sheep 296 infected by the BLV Tax mutant.
To summarize, it appears that, with the exception of a pe-
culiar B/CD8 phenotype in sheep 480, B lymphocytes from
animals infected either by wild-type virus or by the Tax mutant
are indistinguishable. In other words, both types of viruses can
infect and transform similar cell types.
Tax mutant viruses in the transformed cells are not rever-
tants. Since both the evolution of pathogenesis and the cellular
phenotypes associated with the Tax mutant and wild-type virus
were almost identical, our experiments needed an essential
control demonstrating the lack of reversion in the tumor cells.
It was indeed possible that the pathogeneses observed in sheep
296 and 480 were induced by viruses in which the two alanine
mutations at positions 106 and 293 had reverted to a wild-type
serine codon. Therefore, cell lysates were prepared from blood
isolated by jugular venipuncture of sheep 103, 104, 296, and
480. The tax gene fragments were amplified by PCR, and the
corresponding amplicons were subjected to direct sequencing.
As illustrated in Fig. 4, the alanine codons 106 and 293 were
perfectly conserved in all the lysates, demonstrating lack of
reversion of the tax sequences. These analyses were performed
at different time points, including at the terminal stage with
fully transformed tumor cells. In addition, six independent
amplicons were also completely sequenced over a region en-
compassing the entire tax gene. No mutation within all these
samples could ever be identified (data not shown).
We conclude that the pathogeneses observed in sheep 296
and 480 infected by the BLV Tax mutant did not result from a
reversion of the recombinant to a wild-type virus.
DISCUSSION
In this report, we have shown that mutations of the BLV tax
gene that hamper immortalization of primary REFs still allow
the occurrence of leukemogenesis in sheep. These observa-
tions cast light onto contradictory conclusions that might be
drawn from transformation assays performed in cell culture
and experiments in vivo.
A first critique to be answered concerns the lack of reversion
of the recombinants in vivo. In fact, we have shown that the tax
and rex sequences are not mutated after leukemogenesis in two
different sheep (480 and 296; Fig. 4). However, it is possible
that unidentified compensatory mutations occurred in other
parts of the viral genome, for example, in the R3/G4 accessory
genes. Although we have not formally ruled out this possibility
FIG. 4. Direct sequencing of codons surrounding alanines 106 and 293 of the
tax gene in four sheep infected by the BLV Tax mutant. Blood was extracted by
jugular venipuncture of sheep 103, 104, 296, and 480 infected with provirus
pBLVTax1061293. After lysis, partially purified DNA was amplified by PCR
using two primers flanking the tax gene. The resulting amplicons were then
subjected to direct sequencing by PCR and migrated onto a denaturing poly-
acrylamide gel. The sequences surrounding alanines 106 and 293 are indicated.
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by sequencing the entire virus, we think that this is unlikely
because deletion of R3 or G4 provokes a drastic reduction in
the proviral loads (78).
A second point to be discussed concerns the immortalization
assay itself. In our previous study on Tax phosphorylation, we
reported that changing serine residues 106 and 293 into ala-
nines abrogated its immortalization potential in primary REFs.
It remains possible, however, that this type of experiment lacks
sensitivity and reveals only the oncogenes harboring very high
immortalization activity. Alternatively, the REF assay could
be oversensitive, and slight differences in the oncogenic poten-
tial of Tax would generate large phenotypic variations during
transformation in cell culture. However, in our previous stud-
ies (72; unpublished results), systematic screening of a series of
mutants revealed that Tax oncogenic activity remains very fre-
quently conserved, whereas its transactivation potential is de-
stroyed. In fact, the Tax phosphorylation recombinant was the
sole immortalization-deficient mutant that is still able to acti-
vate viral transcription. In other words, most Tax mutants are
negative for transactivation and positive for immortalization,
indicating that the REF assay is not sensitive to various mod-
ifications within Tax.
Another straightforward interpretation of the results would
concern the differential pathways involved in transformation of
REF cells or B lymphocytes. This has been illustrated in the
HTLV system by specific Tax mutants that display various
phenotypes depending on the cell type (3, 42, 57). In particular,
the abilities of some mutants to activate transcription via the
CRE, NFkB, or CArG enhancer elements were different in
Rat-1, REF, and T cells. For example, clone 703 was compe-
tent for the NFkB pathway in the three cell types but displayed
a mixed pattern for activation via the CRE: negative in T
lymphocytes, intermediate in Rat-1 cells, and positive in REFs
(3, 42). This mutant was unable to cooperate with the ras on-
cogene in REF fibroblasts but induced the formation of foci in
soft agar in Rat-1 cells. Furthermore, the same mutant induced
a higher proliferative response and allowed long-term expan-
sion of CD8-positive T lymphocytes. Although the T-lympho-
cyte system appears to be the best mimic of the in vivo situa-
tion, this example illustrates the difficulties encountered during
interpretation of the data. In this context, the availability of an
animal model, such as the infection of sheep by BLV recom-
binants, might cast some light on our understanding of the
leukemogenic process induced by these related viruses. In fact,
there is an intriguing parallel between the phenotypes associ-
ated with HTLV mutant 703 and the BLV Tax recombinant,
allowing us some speculation. Both clones are indeed unable to
transform REF cells in cooperation with the ras oncogene but
exhibit immortalization potential in cell culture and in vivo. In
addition, a peculiar phenotype characterized by the expression
of the CD8 marker occurred in 90% of the T cells transduced
with Tax-I 703 and sheep 480 infected with the BLV Tax
mutant. Although the CD8 marker was not present on the B
lymphocytes from the other sheep (animal 296 infected with
the same mutant) and was not identified at the early stages of
infection (data not shown), the coincidence is appealing. Any-
way, the modification of the target cell phenotype suggests
that the metabolic pathways leading to full transformation are
somehow perturbed. In fact, the emergence of CD41 CD81
double-positive cells has been reported in patients infected
with HTLV-1 (11, 20, 39, 50). Similarly, CD81 T lymphocytes
appear to be the main but not the sole target for the related
HTLV-II virus (9, 21, 35, 40, 67). In contrast, the presence of
a T-cell marker has only very rarely been observed on B lym-
phocytes from patients with large granular or chronic lympho-
cytic leukemia (4, 32).
The generation of B cells harboring T-specific markers in
sheep 480 is a matter of speculation. First, it is possible that a
rare IgM1 CD81 subset already exists in seronegative animals
and that this population is expanded after BLV infection. The
two-color flow cytometry data presented in Fig. 3C would in-
deed suggest that such double-positive cells could be present
among the PBMCs of other sheep. According to this hypoth-
esis, the mutation of the Tax phosphorylation sites could some-
how alter the viral target specificity and yield B lymphocytes
with a CD8 marker. Modification of the cell preference
has been illustrated in cultures of T lymphocytes infected by
HTLV mutants (3, 55). An increased tropism for a given cel-
lular phenotype might be due to better viral replication con-
secutive to, for instance, enhanced expression, receptor recog-
nition, or escape from immune surveillance. In this context, the
ability of Tax to activate the HTLV-1 LTR is greatly increased
in CD41 cells compared to CD8-positive lymphocytes (49).
From our data, it does not appear that the BLV Tax phosphor-
ylation mutant mediates enhanced transcription during tran-
sient-transfection experiments (73) and ex vivo (Fig. 3B). In
addition, based on the evolution of the proviral loads, viral
replication of the Tax mutant also appears unaffected (Fig. 1).
Another hypothesis underlining the generation of IgM1 CD81
cells would be the ability of the Tax mutant to induce the ex-
pression of the CD8 protein. We think that this assumption is
unlikely because (i) transient transfection of the pSGtax1061
293 vector does not augment CD8 RNA transcription in cul-
ture (data not shown) and (ii) the presence of the CD8 mol-
ecule is not always associated with the Tax mutant virus (in the
case of sheep 296). We therefore favor the hypothesis based on
alteration of cell target specificity.
A fact that merits some comment is the imperfect concor-
dance between the presence of the CD8 marker and infection
by the Tax mutant. The CD8 molecule indeed appeared to be
expressed only at the final stage of leukemogenesis (data not
shown), and this phenotype was not observed at any time in
another animal (sheep 296; Fig. 3C). A similar situation holds
true for T lymphocytes immortalized in cell culture by HTLV-
1 Tax mutants, the cell lines generated in vitro being either
CD41, CD81, or double positive (3, 55). In contrast, cells
immortalized by the wild-type Tax-I protein were, in their great
majority, pertaining to CD41 lymphocyte subtypes. Altogeth-
er, these observations indicate that the frequency of an altered
phenotype is increased when the tax gene is mutated. Deter-
mining whether this is a general rule in sheep infected with the
BLV Tax mutant is hampered by experimental restrictions,
such as limited numbers of animals and long latency periods. It
should, however, be mentioned that, in a series of eight tumor
biopsies from sheep infected by wild-type viruses, none of them
were CD8 positive (data not shown). In addition, this marker
has never been associated with BLV-infected cells in naturally
infected cattle (reviewed recently in reference 78). The pres-
ence of the CD8 molecule at the surface of the B lymphocytes
of sheep 480 thus appears to be a very rare event, but the
analogy with other viral systems like HTLV (3) or even other
leukemias in humans (32) is striking (4).
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